Raymond Douglas, MD, PhD, Unveils Research on Six-Week Teprotumumab Dosing to Help Protect Hearing

ConferenceteprotumumabPositive

AI Analysis

Summary

Dr. Raymond Douglas presented research on a six-week teprotumumab dosing regimen designed to help protect hearing in thyroid eye disease patients at the American Society of Ophthalmic Plastic Surgeons conference.

Outcome Details

Research presentation on six-week teprotumumab dosing regimen focused on hearing protection

Importance:3/10

Sentiment:

0.30

teprotumumabthyroid eye diseaseTEDdosing regimenhearing protectionresearch presentationASOPRS

Related Companies

$AHR

Read the original article

Published by PR Newswire Pharma on October 12, 2026 2:42 PM

Read Original